SOURCE: Althea Technologies, Inc.

November 08, 2006 06:00 ET

Althea Technologies to Present at the Upcoming BIOCOM Investors Conference in San Diego

SAN DIEGO, CA -- (MARKET WIRE) -- November 8, 2006 -- Althea Technologies, Inc., a leading provider of innovative technologies and services for pharmaceutical development and manufacturing, announced today that the company will be presenting at the inaugural BIOCOM Investors Conference in San Diego, California during the morning session on November 15, 2006 at the San Diego Marriott Del Mar. BIOCOM is the largest regional life sciences association in the world, representing over 500 member companies in San Diego and Southern California.

Althea Technologies will be reporting on its dynamic growth in pharmaceutical contract manufacturing and will highlight its newest strategic initiative termed eXpress Pathway. Althea's suite of enabling technologies and expertise under this new program will focus on the development of significant gene expression-based biomarkers. The eXpress Pathway program is designed to fast-track targets of clinical utility to drive more effective treatment options. The initiative will provide strategic partnering and co-development opportunities with Althea to enable the development of clinically relevant biomarkers.

Dr. François Ferré, Co-President and Co-CEO, will present at the BIOCOM Investor Conference and was quoted as saying, "Althea's presentation at the BIOCOM Investors Conference is a major milestone for the company. Althea's strong growth is providing opportunities to pursue exciting new opportunities like the eXpress Pathway program, which leverages our innovative technologies and expertise to deliver new biomarkers for the advancement of novel therapeutics and diagnostic tools."

About Althea Technologies, Inc.

Althea Technologies, a leading San Diego-based pharmaceutical services firm, provides critical manufacturing and development services that support researchers worldwide in their advancement of novel therapies and efforts to apply new genomic information. Althea's services include cGMP contract manufacturing of recombinant proteins, DNA-based therapeutics and vaccines, aseptic filling, and gene quantification using real-time PCR and gene expression analysis under GLP conditions. Additionally, Althea has introduced new services and technologies for the identification and development of genetic biomarkers with innovative programs such as the company's proprietary eXpress Pathway(SM). For more information, visit www.altheatech.com.

Contact Information

  • Contact:

    Althea Technologies, Inc.
    Alan Moore
    Executive V.P. and Chief Business Officer
    (858) 882-0205
    Email Contact